



# Updated Paxlovid Guidelines

There are the updated guidelines for who should get Paxlovid (the anti-viral medication for COVID). Note that Paxlovid will transition from federally donated (free) product to commercially purchased product on Tuesday, Jan. 23, 2024. The retail price is \$1,400 for a 5-day course (!!).

## Here is who should be getting Paxlovid for COVID as an outpatient:

- Symptoms for 5 days or less
- No new supplemental oxygen requirement
- Documented positive SARS-CoV-2 test



## One of the following criteria indicating risk of severe disease:

- Age 60 years of age or greater
- Immunosuppressive disease or immunosuppressive treatment
- Chronic lung disease requiring baseline oxygen support (e.g., 2-6L)
- Sickle cell disease
- Cystic fibrosis
- Neurodevelopmental disorders in pediatric patients, not including autism spectrum disorders
- Having a medical-related technological dependence (e.g., tracheostomy, gastrostomy)

**OR**

## Two or more of any of the following conditions (must have at least 2)

- Pregnancy
- Body mass index  $\geq 35$
- Current smoker or chronic lung disease not on baseline oxygen
- Chronic kidney disease
- Chronic liver disease
- Diabetes mellitus
- Stroke/cerebrovascular disease
- Cardiovascular disease

Please review this [excellent article](#) from Yale Medicine with details about the medication Paxlovid.